标题
IL-6 biology: implications for clinical targeting in rheumatic disease
作者
关键词
-
出版物
Nature Reviews Rheumatology
Volume 10, Issue 12, Pages 720-727
出版商
Springer Nature
发表日期
2014-08-19
DOI
10.1038/nrrheum.2014.127
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells
- (2014) E. M. Briso et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
- (2014) M. A. Nowell et al. JOURNAL OF IMMUNOLOGY
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1
- (2013) Daniel E Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
- (2013) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature
- (2013) Archana Jain et al. Immunotherapy
- IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
- (2013) Hong Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Trp53 Deficiency Protects against Acute Intestinal Inflammation
- (2013) M. E. Spehlmann et al. JOURNAL OF IMMUNOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Immune mechanisms in medium and large-vessel vasculitis
- (2013) Cornelia M. Weyand et al. Nature Reviews Rheumatology
- Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
- (2013) Jamie Robertson et al. Nature Reviews Rheumatology
- Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
- (2013) Geraldine Navarro et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
- (2013) Jürgen Scheller et al. SEMINARS IN IMMUNOLOGY
- Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
- (2013) Ricardo C. Ferreira et al. PLoS Genetics
- Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis
- (2013) A. Thiolat et al. Arthritis & Rheumatology
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
- (2012) Monika M Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
- (2012) Hubert de Boysson et al. CLINICAL RHEUMATOLOGY
- Hitting a complex target: an update on interleukin-6 trans-signalling
- (2012) Georg H Waetzig et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
- (2012) Jan Sodenkamp et al. IMMUNOBIOLOGY
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
- (2012) J. Hoge et al. JOURNAL OF IMMUNOLOGY
- The interleukin 6 pathway and atherosclerosis
- (2012) Jürgen Scheller et al. LANCET
- Inflammatory bone loss: pathogenesis and therapeutic intervention
- (2012) Kurt Redlich et al. NATURE REVIEWS DRUG DISCOVERY
- Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
- (2012) S. Unizony et al. ARTHRITIS CARE & RESEARCH
- Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica
- (2012) Bernd C. Kieseier et al. JAMA Neurology
- Therapeutic Targeting of the Interleukin-6 Receptor
- (2011) Toshio Tanaka et al. Annual Review of Pharmacology and Toxicology
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*
- (2011) Tanja Barkhausen et al. CRITICAL CARE MEDICINE
- The value of blocking IL-6 outside of rheumatoid arthritis: current perspective
- (2011) Miho Murakami et al. CURRENT OPINION IN RHEUMATOLOGY
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Tocilizumab: a novel therapy for patients with large-vessel vasculitis
- (2011) C. Salvarani et al. RHEUMATOLOGY
- ADAM17: a molecular switch to control inflammation and tissue regeneration
- (2011) Jürgen Scheller et al. TRENDS IN IMMUNOLOGY
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
- (2010) G. D. Kitas et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Is Interleukin-6 Receptor Blockade the Holy Grail for Inflammatory Diseases?
- (2010) M A Febbraio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Interleukin-6 as a Therapeutic Target in Candidate Inflammatory Diseases
- (2010) N Nishimoto CLINICAL PHARMACOLOGY & THERAPEUTICS
- Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice
- (2010) Athena Chalaris et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
- (2010) K. HAGIHARA et al. JOURNAL OF RHEUMATOLOGY
- Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases
- (2010) Olaf Schultz et al. PLoS One
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
- (2010) Y. Shima et al. RHEUMATOLOGY
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
- (2009) S. Matsumoto et al. JOURNAL OF IMMUNOLOGY
- Heterogeneity of human effector CD4+ T cells
- (2009) Francesco Annunziato et al. ARTHRITIS RESEARCH & THERAPY
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells
- (2008) T. Korn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now